首頁 > 市場調查報告書 > 製藥

消化器

市場調查報告書

商品編碼

1550600

發炎性腸道疾病市場：依藥物類別、適應症、給藥途徑、通路和地區分類

Inflammatory Bowel Disease Market, By Drug Class, By Disease Indication, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2024年07月30日 | 出版商:

Coherent Market Insights | 英文 167 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球發炎性腸道疾病（IBD）市場規模為223.1億美元，預計到2031年將達301億美元，2024年至2031年複合年成長率為4.4%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	223.1億美元
實際資料	2019-2023	預測期	2024年至2031年
預測 2024-2031 年複合年成長率：	4.40%	2031年價值預測	301億美元

圖：2024 年按地區分類的發炎性腸道疾病市場佔有率 (%)

發炎性腸道發炎性腸道疾病（IBD）是指克隆氏症和潰瘍性大腸炎這兩種疾病，其特徵是胃腸道內的慢性發炎。 IBD 主要影響小腸和大腸，但有時也會涉及消化器官系統的其他部分。 IBD 的典型症狀因患者而異，但通常包括反覆腹痛、腹瀉、嘔吐、體重減輕和疲勞。儘管確切的原因尚不清楚，但人們認為 IBD 的發生是由於遺傳易感患者對環境觸發因素的免疫反應調節不當所致。目前可用的治療方法旨在透過針對免疫系統的各個組成部分來誘導和維持緩解。由於這些治療方法無法治愈，IBD 在全世界造成了巨大的臨床和經濟負擔。

市場動態：

全球發炎性腸道疾病性腸道疾病市場的成長主要是由於生活方式的改變、環境風險的增加以及已開發國家預期壽命的增加而導致克隆氏症和潰瘍性大腸炎盛行率上升。市場成長也受到以下因素的推動：專注於開發新型選擇性和個人化療法的研究活動的活性化、對 IBD 早期診斷和管理的認知不斷提高以及主要市場醫療保健成本的上升。然而，嚴格的藥物開發法規以及與 IBD 診斷工具和藥物相關的高成本可能會阻礙市場成長。生物製藥、幹細胞、基因治療等領域的研究和開發進展可能為相關人員提供利潤豐厚的機會。

本研究的主要特點

該報告對全球發炎性腸道疾病市場進行了詳細分析，以2023年為基準年估計了預測期內（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
該報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球發炎性腸道疾病市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球發炎性腸道疾病市場的各種策略矩陣，將有助於相關人員做出決策。

公司簡介
- AbbVie Inc.
- Johnson &Johnson Services, Inc.
- Takeda Pharmaceutical Company Limited
- Biogen
- Amgen Inc.
- UCB SA
- Novartis AG
- Merck &Co., Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Gilead Sciences
- Bausch Health Companies Inc.
- Celltrion Healthcare Co., Ltd.
- CELGENE CORPORATION
- COSMO PHARMACEUTICALS
- Innovate Biopharmaceuticals
- Sandoz
- Horizon Therapeutics

第11章分析師建議

命運之輪
分析師觀點
一致的機會圖

第12章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI4634

Global inflammatory bowel disease market is estimated to be valued at USD 22.31 Bn in 2024 and is expected to reach USD 30.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 22.31 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	4.40%	2031 Value Projection:	US$ 30.10 Bn

Figure. Inflammatory Bowel Disease Market Share (%), By Region 2024

Inflammatory Bowel Disease Market - IMG1

Inflammatory bowel disease (IBD) refers to two conditions - Crohn's disease and ulcerative colitis - that are characterized by chronic inflammation within the gastrointestinal tract. IBD predominantly affects the small and large intestines but can sometimes extend throughout other areas of the digestive system. Typical symptoms of IBD vary between patients but often include recurring abdominal pain, diarrhea, vomiting, weight loss, and fatigue. While the precise etiologies remain unclear, IBD is believed to arise due to inappropriately regulated immune responses to environmental triggers in genetically susceptible individuals. Currently available treatment options aim to induce and maintain remission by targeting different components of the immune system. As these approaches are not curative, IBD poses a substantial clinical and economic burden worldwide.

Market Dynamics:

Global inflammatory bowel disease market growth is primarily driven by rising prevalence of Crohn's disease and ulcerative colitis due to lifestyle changes, growing environmental risks, and prolonged lifespan in developed nations. Increasing research activities focused on developing novel selective and personalized therapies, growing awareness about early diagnosis and management of IBD, and rising healthcare expenditure across major markets can also drive the market growth. However, stringent drug development regulations and high costs associated with IBD diagnostic tools and medications can hamper the market growth. Ongoing R&D in biologics, stem cell and gene-based therapies can offer lucrative opportunities for stakeholders.

Key Features of the Study:

This report provides in-depth analysis of the global inflammatory bowel disease market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
Key companies covered as a part of this study include AbbVie, Janssen Biotech, Takeda Pharmaceutical, UCB, and Pfizer
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global inflammatory bowel disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inflammatory bowel disease market

Detailed Segmentation-

By Drug Class
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- Immunosuppressant
- Antibiotics
- Others
By Disease Indication
- Ulcerative Colitis
- Crohn's Disease
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- AbbVie Inc.
- Johnson & Johnson Services, Inc.
- Takeda Pharmaceutical Company Limited
- Biogen
- Amgen Inc.
- UCB S.A.
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Gilead Sciences
- Bausch Health Companies Inc.
- Celltrion Healthcare Co., Ltd.
- CELGENE CORPORATION
- COSMO PHARMACEUTICALS
- Innovate Biopharmaceuticals
- Sandoz
- Horizon Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Disease Indication
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Inflammatory Bowel Disease Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Inflammatory Bowel Disease Market, By Drug Class, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Aminosalicylates
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
TNF Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Immunosuppressant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Inflammatory Bowel Disease Market, By Disease Indication, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Ulcerative Colitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Crohn's Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Inflammatory Bowel Disease Market, By Route of Administration, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Injectable
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Inflammatory Bowel Disease Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Inflammatory Bowel Disease Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Company Profiles
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Johnson & Johnson Services, Inc.
- Takeda Pharmaceutical Company Limited
- Biogen
- Amgen Inc.
- UCB S.A.
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Gilead Sciences
- Bausch Health Companies Inc.
- Celltrion Healthcare Co., Ltd.
- CELGENE CORPORATION
- COSMO PHARMACEUTICALS
- Innovate Biopharmaceuticals
- Sandoz
- Horizon Therapeutics